By Daniella Parra
Prenetics Global Limited (NASDAQ: PRE) and Prof. Dennis Lo, the Li Ka Shing Professor of Medicine of the Chinese University of Hong Kong have formed a joint venture named Insighta, aiming to revolutionize multi-cancer early detection screening.
The transaction, valued at $200 million, will leverage Prof. Lo’s “FRAGMA” technology for cancer screening, led by a six-person board of directors, with Prof. Lo as Chairman and Danny Yeung as CEO.
“Insighta is dedicated to introducing a breakthrough technology, “FRAGMA”. The science behind Presight holds immense potential for multi-cancer early detection. Epigenetics studies the modifications of DNA that affect its behaviour without changing the DNA sequence. Fragmentation patterns of plasma DNA can be used as an epigenetics-based cancer test with high accuracy and a simple workflow. Another key distinguishing hallmark of Presight is its cost-effectiveness,” Prof. Dennis Lo said. “This innovation doesn’t merely represent a significant leap in cancer detection—it has the potential to transform millions of lives and change the trajectory of cancer prognosis, offering hope where it was once scarce.”